Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 4/20 | 0.64 |
| ▸ | PRSS1 | P07477 | 10/20 | 0.61 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.61 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.61 |
| ▸ | F2 | P00734 | 8/20 | 0.54 |
| ▸ | PLG | P00747 | 1/20 | 0.53 |
| ▸ | C1S | P09871 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1085083 | 0.98 | F10 (0.62) | F10PRSS1PRSS2PRSS3F2 | |
| SCHEMBL29448761 | 0.82 | PARP1 (0.61) | F10 | |
| SCHEMBL17191010 | 0.82 | F10 (0.50) | F10PRSS1PRSS2PRSS3 | |
| SCHEMBL31322467 | 0.82 | F10 (0.47) | F10 | |
| SCHEMBL26070122 | 0.82 | F10 (0.47) | F10PRSS1PRSS2PRSS3 | |
| SCHEMBL23062938 | 0.82 | F10 (0.47) | F10 | |
| SCHEMBL711132 | 0.82 | PARP1 (0.61) | F10 | |
| Hydrochloric Acid SCHEMBL1268771 | 0.81 | PARP1 (0.59) | F10 | |
| SCHEMBL1580873 | 0.79 | KAT6A (0.46) | F10 | |
| SCHEMBL29478758 | 0.79 | KAT6A (0.46) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120019049-A | Azole modulators of cholesterol biosynthesis and their use for promoting remyelination | 基因泰克公司 | 2025-05-16 | — | — | CN | disclosed |
| US-10112931-B2 | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH | NOVARTIS AG (CH) | 2018-10-30 | — | — | US | disclosed |
| US-20180051015-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | NOVARTIS AG (CH) | 2018-02-22 | — | — | US | disclosed |
| US-9688672-B2 | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH | NOVARTIS AG (CH) | 2017-06-27 | — | — | US | disclosed |
| US-20160318915-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | NOVARTIS AG (CH) | 2016-11-03 | — | — | US | disclosed |
| CN-1713907-B | N-substituted pyrrolidine derivatives as dipeptidyl peptidase IV inhibitors | HOFFMANN LA ROCHE | 2010-05-26 | — | — | CN | disclosed |
| CN-1713907-A | N-substituted pyrrolidine derivatives as dipeptidyl peptidase IV inhibitors | HOFFMANN LA ROCHE (CH) | 2005-12-28 | — | — | CN | disclosed |
| WO-1997000612-A1 | ARTHROPODICIDAL AND FUNGICIDAL CYCLIC AMIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1997-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180051015-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | IDH1, IDH3B, IDH3A | F10 4064/4885PRSS1 2859/4885PRSS2 4137/4885 |
| US-20160318915-A1 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH | IDH1, IDH3B, IDH3A | F10 4064/4885PRSS1 2859/4885PRSS2 4137/4885 |
| US-10112931-B2 | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH | IDH1, IDH3B, IDH3A | F10 4064/4885PRSS1 2859/4885PRSS2 4137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.